Literature DB >> 15567938

Reproducible immunohistochemical criteria based on multiple raters' judgments for expression of thymidine phosphorylase in breast cancer tissue.

Hitoshi Tsuda1, Futoshi Akiyama, Masafumi Kurosumi, Goi Sakamoto.   

Abstract

In order to accurately determine the expression of thymidine phosphorylase (TP) in breast cancer, it is important to develop an appropriate system for immunohistochemical staining evaluation. Three raters, pathologists A-C, independently judged the status of TP in both cancer cells and cancer stromal tissue in 586 breast cancers immunohistochemically. TP expression levels were categorized into four groups (scores 0-3), and scores of 2 and 3 were considered as positive. Interrater and intrarater agreement levels in the judgment of TP expression were analyzed by the kappa statistics. By combining three raters' judgments, we sought for the optimal evaluation system that generates the best concordance among all judgments. The numbers of TP-positive cases were 294 (50.2%), 309 (52.1%) and 344 (58.7%) for cancer cells and were 315 (53.8%), 383 (65.4%) and 397 (67.7%) for cancer stromal tissue in the judgments by pathologists A, B, and C, respectively. There was no correlation of TP immunostaining between cancer cells and cancer stroma tissue. Interrater agreement levels were substantial for cancer cells (kappa = 0.652) and moderate for cancer stroma tissue (kappa = 0.438). Intrarater agreement level for TP judgment by pathologists A, B, or C was substantial to almost perfect for cancer cells (kappa = 0.755-0.880), and for cancer stromal tissue (kappa = 0.620-0.752). The level of TP expression estimated under the majority system and the total scoring system setting a cut-off score between 4 and 5 revealed the highest concordance with the three raters' judgments. To accurately evaluate the TP status in breast cancer tissue, three or more raters are needed and the majority system and total scoring system appear appropriate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567938     DOI: 10.1023/B:BREA.0000036797.86601.cc

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  3 in total

1.  High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.

Authors:  Shinobu Umemura; Masatoshi Shirane; Susumu Takekoshi; Yutaka Tokuda; Kazushige Mori; Robert Y Osamura
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

2.  Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis.

Authors:  Anna Lisa Tedeschi; Zohreh Eslami; Evgenia Garoufalis; Ramy R Saleh; Atilla Omeroglu; Gulbeyaz Altinel; Maria Ait-Tihyaty; Bertrand Jean-Claude; Catalin Mihalcioiu
Journal:  Onco Targets Ther       Date:  2015-04-21       Impact factor: 4.147

3.  Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).

Authors:  Gabriel Rinnerthaler; Simon Peter Gampenrieder; Andreas Petzer; Michael Hubalek; Edgar Petru; Margit Sandholzer; Johannes Andel; Marija Balic; Thomas Melchardt; Cornelia Hauser-Kronberger; Clemens A Schmitt; Hanno Ulmer; Richard Greil
Journal:  Ther Adv Med Oncol       Date:  2021-10-19       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.